Navigation Links
OncoSec Medical to Present at Noble Financial Capital Markets' Ninth Annual Equity Conference on January 22
Date:1/17/2013

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon , President and CEO, will present at the Noble Financial Capital Markets' Ninth Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22 at 12:30 PM Eastern Time.

(Logo:  http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

At the time of the presentation, a live audio and high-definition video webcast of OncoSec's presentation will be available through the Noble Financial website: www.noblefcm.com. It is recommended that those who are interested should register at least 10 minutes prior to the start of the presentation to ensure timely access. A Microsoft Silverlight viewer, available for free download from the presentation link, will be required to participate.

In addition, OncoSec will be a sponsor of the European School of Dermato-Oncology (EADO) meeting in Berlin, Germany from January 17-19. Company delegates will be attending and participating in the meeting.

About Noble Financial Capital Markets

Noble Financial Capital Markets was established in 1984 and is an equity research driven, full-service, investment banking boutique focused on life sciences, technology and media, emerging growth, companies. The company has offices in New York, Boston, New Jersey, Los Angeles, and Boca Raton, FL. For more information: www.noblefcm.com

About the European School of D
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based ... spinal cord injury (SCI) treatment with their novel Neuro-Spinal ... tissue regrowth in the spinal cord area when cells ... approved polymer, the scaffold ultimately breaks down to water ... body. NVIV has recently attracted significant investor attention with ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... policy , , ROCHESTER, Minn., ... use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, ... alcohol. The results of the study are published in the December ... , VIDEO ALERT: Additional audio and video ...
... VICL ) announced today the receipt of a $1.0 ... Merck,s planned initiation of a Phase I clinical trial of ... is based on Vical,s DNA gene delivery technology and encodes ... separate license agreement. , , ...
Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... in the war on asthma symptom control could be a ... that Mom and Dads leeriness towards their childrens asthma medications ... health risks that outweigh the benefits might explain to ... children with the wheezing, coughing and trouble-breathing disease do not ...
... Consultech Strengthens Omnicom,s Presence in China,s Growing ... ... Omnicom Group Inc.,("Omnicom") (NYSE: OMC ), the leading global ... Services,division ("DAS"), a majority ownership interest in Consultech, a leading,healthcare ...
... The American,Psychiatric Association (APA) applauds the U.S. Food and ... led to the,approval of a new treatment for two ... the approvals are a result of the federal,Best Pharmaceuticals ... that leads to this kind of approval, given that ...
... 180 day shared exclusivity on the product, ... announced today that the Company has received tentative ... manufacture and market,Galantamine Hydrobromide Tablets, 4mg (base), 8mg ... treatment of mild to moderate dementia of,the Alzheimer,s ...
... the best drug treatment for their disease, because family doctors ... in the Archives of Disease in Childhood. , Around ... disease prompts up to a third of children aged between ... researchers used national data to calculate the number of prescriptions ...
... in This Region,Deep Commitment to this Market Evidenced in Opening of ... ... and PHILADELPHIA, Sept. 3 Rohm,and Haas Company (NYSE: ROH ... in India to meet,growing demand for its environmentally advanced products and ...
Cached Medicine News:Health News:Parents' perceptions can hamper kids' asthma care, study finds 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 3Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis 2Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Rohm and Haas Expands in India 2Health News:Rohm and Haas Expands in India 3Health News:Rohm and Haas Expands in India 4
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Ideal for short scleral tunnel and trabecular meshwork incisions...
30 Pre-formed and razor sharp...
Medicine Products: